Mynosys Receives $1 Million Grant from NEI to Commercialize Zepto

August 4, 2017: By Jon Swedien
Mynosys Zepto disposable handpiece

Mynosys’ Zepto disposable handpiece

Mynosys has received a $1 million government grant to commercialize its Zepto capsulotomy system, the Fremont, California, company announced Aug. 1.

The National Eye Institute (NEI) of the National Institutes of Health (NIH) awarded Mynosys an SB1 Commercialization Readiness Program award, which is intended to support the transition of previously NIH-funded projects to the commercialization stage. Mynosys has received $5.3 million in total from the NIH’s Small Business Innovation Research program.

The Zepto, which received US 501(k) clearance in June, is designed to allow cataract surgeons to create automated, circular, exactly sized capsulotomies tailored to the individual patient.

The system is the first non-laser automated cataract capsulotomy device to gain US approval, but several others are expected to follow. The device received CE marking in December 2015.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022